This Article Full Text Full Text (PDF) Correction (v113,pe742) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khan, N. A. Articles by Levin, A. Search for Related Content PubMed PubMed Citation Articles by Khan, N. A. Articles by Levin, A. Pubmed/NCBI databases Substance via MeSH Related Collections Chronic ischemic heart disease Epidemiology Other diagnostic testing Risk Factors

(Circulation. 2005;112:3088-3096.)
© 2005 American Heart Association, Inc.

Epidemiology

Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease

A Meta-Analysis

Nadia A. Khan, MD, MSc, FRCPC; Brenda R. Hemmelgarn, PhD, MD, FRCPC; Marcello Tonelli, MD, MSc, FRCPC; Christopher R. Thompson, MD, CM, FRCPC; Adeera Levin, MD, FRCPC

From the Division of Internal Medicine (N.A.K.), Division of Cardiology (C.R.T.), and Division of Nephrology (A.L.), University of British Columbia, and the Division of Nephrology, University of Calgary, Calgary (B.R.H.), and the Division of Nephrology, University of Alberta, Edmonton (M.T.), Alberta, Canada.

Correspondence to Nadia A. Khan, MD, 620-B 1081 Burrard St, Vancouver, BC, Canada, V6Z 1Y6 E-mail nakhan{at}shaw.ca

Received May 4, 2005; accepted July 25, 2005.

Background— The prognostic usefulness of troponin enzymes in end-stage renal disease (ESRD) patients is controversial. To resolve this uncertainty of troponin as a prognostic tool, we conducted a systematic review to quantify the association between elevated troponin I or T and long-term total mortality among ESRD patients not suspected of having acute coronary syndrome.

Methods and Results— We conducted an unrestricted search from the MEDLINE, EMBASE, and DARE bibliographic databases to December 2004 using the terms troponin.mp. or exp troponin and exp kidney, exp renal, exp kidney disease exp renal replacement therapy. We also manually searched review articles and bibliographies to supplement the search. Studies were included if they were prospective observational studies, used cardiac-specific troponin assays, and evaluated long-term risk of death or cardiac events for asymptomatic ESRD patients. Two authors independently abstracted data on study and patient characteristics. Studies findings were stratified according to troponin T or I levels. We used a random-effects model to pool study results and tested for heterogeneity using ² testing and used funnel-plot inspection to evaluate the presence of publication bias. Data from 28 studies (3931 patients) published between 1999 and December 2004 were included in this review. Patients received dialysis for a median duration of 4 years, with a mean follow-up of 23 months. From the pooled analysis, elevated troponin T (>0.1 ng/mL) was significantly associated with increased all-cause mortality (relative risk, 2.64; 95% CI, 2.17 to 3.20). Although the prognostic effect sizes were all consistent with a positive relationship between troponin T and mortality, there was significant heterogeneity in the magnitude of these effect sizes (P=0.015). The funnel plot showed evidence of publication bias. Elevated troponin T was also strongly associated with increased cardiac death. Studies evaluating troponin I included a wide variety of assays and differing cut points, rendering synthesis of the study findings difficult.

Conclusions— Elevated troponin T (>0.1 ng/mL) identifies a subgroup of ESRD patients who have poor survival and a high risk of cardiac death despite being asymptomatic. These findings suggest that troponin T is a promising risk stratification tool and may help frame therapeutic decisions. The clinical interpretation of elevated troponin I levels, however, remain unclear, largely because of the lack of standardization of assays.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				D. C Gaze and P. O Collinson Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance Ann Clin Biochem, July 1, 2008; 45(4): 349 - 355. [Abstract] [Full Text] [PDF]

				T. Hayashi, Y. Obi, T. Kimura, K.-i. Iio, S. Sumitsuji, Y. Takeda, Y. Nagai, and E. Imai Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy Nephrol. Dial. Transplant., April 10, 2008; (2008) gfn181v1. [Abstract] [Full Text] [PDF]

				P. A. McCullough Coronary Artery Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 611 - 616. [Abstract] [Full Text] [PDF]

				A. Yee-Moon Wang, C. Wai-Kei Lam, M. Wang, I. Hiu-Shuen Chan, W. B. Goggins, C.-M. Yu, S.-F. Lui, and J. E Sanderson Prognostic Value of Cardiac Troponin T Is Independent of Inflammation, Residual Renal Function, and Cardiac Hypertrophy and Dysfunction in Peritoneal Dialysis Patients Clin. Chem., May 1, 2007; 53(5): 882 - 889. [Abstract] [Full Text] [PDF]

				F. S. Apple, A. S. Jaffe, and C. A. Herzog Letter Regarding Article by Khan et al, "Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease: A Meta-Analysis" Circulation, May 23, 2006; 113(20): e775 - e775. [Full Text] [PDF]

				N. A. Khan, B. R. Hemmelgarn, M. Tonelli, C. R. Thompson, and A. Levin Response to Letter Regarding Article by Khan et al, "Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease: A Meta-Analysis" Circulation, May 23, 2006; 113(20): e776 - e776. [Full Text] [PDF]

				C. R. Henry, D. Satran, B. Lindgren, C. Adkinson, C. I. Nicholson, and T. D. Henry Myocardial Injury and Long-term Mortality Following Moderate to Severe Carbon Monoxide Poisoning JAMA, January 25, 2006; 295(4): 398 - 402. [Abstract] [Full Text] [PDF]

				M. S. Lauer Cardiac Troponins and Renal Failure: The Evolution of a Clinical Test Circulation, November 15, 2005; 112(20): 3036 - 3037. [Full Text] [PDF]